Omata M, Tada M
Department of Gastroenterology, University of Tokyo, Japan.
Nihon Geka Gakkai Zasshi. 2000 Feb;101(2):233-6.
Genetic changes in K-ras, p53, p16, DPC4, and telomerase activity are frequent in pancreatic adenocarcinoma. The incidence of these changes has been reported to be approximately 80% for K-ras, 50% for p53, p16, and DPC4, and 90% for telomerase activity. Genetic abnormalities of APC and microsatellite instability are relatively rare (less than 10%) in pancreatic carcinoma. Among these genetic abnormalities, K-ras and telomerase activity have been used as molecular markers for the diagnosis of pancreatic carcinoma. K-ras mutation could be considered as an early event in the progression to malignancy and thus it has no clear association with the prognosis of the carcinoma. In contrast, mutation of p53 could be a prognostic indicator.
K-ras、p53、p16、DPC4基因改变以及端粒酶活性在胰腺腺癌中很常见。据报道，这些改变的发生率在K-ras约为80%，在p53、p16和DPC4约为50%，在端粒酶活性约为90%。APC基因异常和微卫星不稳定性在胰腺癌中相对少见（低于10%）。在这些基因异常中，K-ras和端粒酶活性已被用作胰腺癌诊断的分子标志物。K-ras突变可被视为恶性进展中的早期事件，因此它与癌的预后无明确关联。相比之下，p53突变可能是一个预后指标。
